Research ArticleResearch Article

Short–term Intensive Neoadjuvant Chemotherapy Improving 10–year Survival for Patients with Stage II and Operable Stage III Breast Cancer

Bin Zhang, Yue Cai, Qi Zhang, Ziwei Ying, Shuling Jiang, Hong Xu, Yongxue Zheng and Daqing Jiang
Chinese Journal of Clinical Oncology February 2004, 1 (1) 42-46;

Article Figures & Data

Tables

  • Table 1.

    Characteristics of patients enrolled in group A and B

     Group AGroup B
    No. of patients251259
    Age23–6624–68
    Stage
        IIA7589
        IIB105117
        IIIA4330
        IIIB2823
    Histology of breast cancer
        Non–special infiltrating246253
        Special infiltrating56
    Menopausal status
        Premenopausal184188
        Postmenopausal6771
    No. of ER status246215
        ER (+)145(59.0%)114(53.0%)
        ER (–)101101
  • Table 2.

    Protocol of pre– and postoperative chemotherapy

    ProtocolDosagePreoperative–Postoperative–
    CMF
    Cyclophosphamide(C)500mg/m2, ivWeekly ×4Days 1, 8
    Methotrexale(M)40mg/m2, iv every 28 day for one cycle
    5–Fu(F)500mg/m2, iv rip  
    FAC
    5–Fu(F)500mg/m2, iv rip1st and 3rd week with FACDay1 with FAC, Day8 with F
    Adramycin(A)40mg/m2, iv2nd and 4th week with FCevery 21 days for one cycle
    Cyclophosphamide(C)500mg/m2, iv  
  • Table 3.

    OS and DFS at 5–year and 10–year in groups Table bothgroups No(percent)

    StageGroupAGroupBP value
    OSDFSOSDFS
    5–year
        II147/180(81.7)142/180(78.9)169/206(82.0)160/206(77.7) 
        III42/71(59.2)39/71(54.9)15/53(28.3)11/53(20.8)P<0.05
            IIIA26/43(60.5)24/43(55.8)9/30(30.0)7/30(23.3)P<0.05
            IIIB16/28(57.1)15/28(53.6)6/23(26.1)4/23(17.4)P<0.05
    10–year
        II118/151(78.1)111/151(73.5)134/196(68.4)119/196(60.7)P<0.05
        III22/52(42.3)21/52(40.4)10/49(20.4)9/49(18.4)P<0.05
  • Table 4.

    Relationship between OS and TN status in A and B (percent)

     GroupAGroupBP value
    5–year
        T12/2(100.0)42/47(89.4)P< 0.05
        T2142/179(79.3)132/178(74.2)P<0.05
        T333/48(68.8)8/21(38.1) 
        T412/22(54.5)2/13(15.4) 
      N(–)83/102(81.4)95/116(81.9) 
      N(+)106/149(71.1)89/143(62.2) 
            1–367/84(79.8)57/69(82.6) 
            ≥439/65(60.0)32/74(43.2)P<0.05
    10–year
        T12/2(100.0)35/47(74.5) 
        T2107/149(71.8)104/164(63.4) 
        T325/40(62.5)4/21(19.0)P<0.05
        T46/12(50.0)1/13(7.7)P<0.05
      N(–)82/102(80.4)89/116(76.7) 
      N(+)58/101(57.4)55/129(42.6)P<0.05
            1–336/60(60.0)40/74(54.1) 
            ≥422/41(53.7)15/55(27.0)P<0.01
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords